January 10, 2014—The Health Resources and Services Administration (HRSA) yesterday released the remaining two summaries of the 51 audits of 340B covered entities it performed in fiscal year 2012. HRSA's latest update also includes brief descriptions of how some audits were resolved. Many of the audits are still not final, however. … [Read more...]
340B Drug Purchases Are Just Shy of $7 Billion Annually
HRSA supplies figure in a filing in orphan drug exclusion lawsuitJanuary 9, 2014—The dollar amount of pharmaceuticals purchased through the 340B program has been a guesstimate—until now. … [Read more...]
Hospitals Provided $45.9 Billion in Uncompensated Care in 2012, Study Shows
1 in 3 Americans incur medical debts, mainly due to high cost-sharing plans, separate report findsJanuary 8, 2014—U.S. hospitals provided a record-high $45.9 billion in unreimbursed care to indigent and underinsured patients in 2012, an 11.7 percent increase over 2011, according to a new American Hospital Association (AHA) report. … [Read more...]
PhRMA: Strike 340B Data in Orphan Drug Case
PhRMA has asked a federal judge to strike a hospital survey from a friend-of-the court brief filed by 340B healthcare providers. … [Read more...]
Hospitals Provided $45.9 Billion in Uncompensated Care in 2012
U.S. hospitals provided a record-high $45.9 billion in unreimbursed care to indigent and underinsured patients in 2012, an 11.7 percent increase over 2011, according to a new American Hospital Association (AHA) report. The uncompensated care total includes charity care and bad debt but excludes Medicaid and Medicare underpayment. 340B hospitals provide 62 percent of all … [Read more...]
Merck Announces 340B Refunds
Drugs Range from Remeron to FollistimPharmaceutical manufacturer Merck Sharp & Dohme Corp. has announced it will give refunds to 340B providers that bought certain products between 2002 and 2013. … [Read more...]
Hospitals Ask Court to Uphold Orphan Drug Rule
Support Broader Use Under 340BOrganizations representing safety-net healthcare providers filed a friend-of-the-court brief Dec. 20 supporting a Department Health and Human Services (HHS) rule that allows many of their members to receive discounted pricing on “orphan” drugs when not used to treat rare diseases. … [Read more...]